Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis

Gene Therapy

Volumn 9, Issue 4, 2002, Pages 291-296

  Liu, S C ^a   Minton, N P ^b   Giaccia, A J ^a   Brown, J M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

5 fluorocytosine; 5 fluorouracil; Clostridium sporogenes; Cytosine deaminase; Gene therapy; Hypoxia

Indexed keywords

CYTOSINE DEAMINASE; DNA; FLUCYTOSINE; FLUOROURACIL;

ANAEROBIC BACTERIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL SPORE; CLOSTRIDIUM SPOROGENES; CONTROLLED STUDY; DNA VECTOR; DRUG EFFICACY; DRUG SELECTIVITY; ESCHERICHIA COLI; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSFORMATION; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR NECROSIS;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CLOSTRIDIUM; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; MICE; MICE, INBRED C3H; NECROSIS; NEOPLASM TRANSPLANTATION; NUCLEOSIDE DEAMINASES; PRODRUGS;

ANIMALIA; BACTERIA (MICROORGANISMS); CLOSTRIDIUM; CLOSTRIDIUM SPOROGENES; ESCHERICHIA COLI; POSIBACTERIA;

EID: 85047697737     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301659     Document Type: Article

References (23)

1. Chemotherapeutic tumour targeting using clostridial spores
2. Anaerobic bacteria as a delivery system for cancer gene therapy: Ativation of 5-fluorocytosine by genetically engineered clostridia
3. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment
4. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration
5. Onkolyseversuche mit apathogenen anaeroben Sporenbildern am Ehrlich Tumor des Maus
6. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma
7. Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors
8. Oncolysis by clostridia V. Transplanted tumors of the hamster
9. Clostridial oncolysis in man
10. The liquefaction (oncolysis) of malignant gliomas by a non-pathogenic clostridium
11. Oncolysis of malignant gliomas of the brain
12. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts
13. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine
14. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity
15. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts
16. Tumor-targeted Salmonella as a novel anticancer vector
17. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo
18. Quantitative investigations into the elimination of in vitro-obtained spores of the non-pathogenic Clostridium butyricum strain CNRZ 528, and their persistence in organs of different species following intravenous spore administration
19. Further progress with oncolysis due to apathogenic clostridia
20. Unraveling immune privilege
21. Enhancement of CCNU cytotoxicity by misonidazole: Possible therapeutic gain
22. Clostridial cloning vectors
23. Introduction of plasmids into whole cells of Clostridium acetobutylicum by electroporation